000137116 001__ 137116
000137116 005__ 20240321220207.0
000137116 0247_ $$2doi$$a10.1097/WCO.0b013e3283632da6
000137116 0247_ $$2pmid$$apmid:23812308
000137116 0247_ $$2pmc$$apmc:PMC4196800
000137116 0247_ $$2ISSN$$a1350-7540
000137116 0247_ $$2ISSN$$a1473-6551
000137116 0247_ $$2altmetric$$aaltmetric:1593541
000137116 037__ $$aDZNE-2020-03438
000137116 041__ $$aEnglish
000137116 082__ $$a610
000137116 1001_ $$0P:(DE-HGF)0$$aStamelou, Maria$$b0$$eCorresponding author
000137116 245__ $$aAtypical parkinsonism: an update.
000137116 260__ $$a[S.l.]$$bOvid$$c2013
000137116 264_1 $$2Crossref$$3print$$bOvid Technologies (Wolters Kluwer Health)$$c2013-08-01
000137116 3367_ $$2DRIVER$$aarticle
000137116 3367_ $$2DataCite$$aOutput Types/Journal article
000137116 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1588933458_10353$$xReview Article
000137116 3367_ $$2BibTeX$$aARTICLE
000137116 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137116 3367_ $$00$$2EndNote$$aJournal Article
000137116 520__ $$aThis update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism published over the past 2 years.A genome-wide association study identified new genetic risk factors for progressive supranuclear palsy and new genetic conditions presenting with atypical parkinsonism have been described. The clinical criteria for diagnosis of corticobasal degeneration have been revised, and for progressive supranuclear palsy are under revision. Novel molecular techniques to identify possible biomarkers, as in other neurodegenerative disorders, have started being studied on atypical parkinsonian conditions, and although preliminary results seem promising, further studies are urgently warranted. Therapeutic trials based on disease-specific targets have shown no clinical improvement.The knowledge obtained recently on atypical parkinsonian conditions points out the major deficits in this field. With the expanding phenotypical spectrum of atypical parkinsonian conditions, the early identification of patients has become difficult. The inability of conventional methods to identify these disorders earlier and better than clinicians, and the recent failure of promising therapeutic compounds, highlight the fact that the lack of biomarkers is probably the greatest limitation for developing treatments for these disorders. Thus, current and future research in this direction will be crucial.
000137116 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000137116 588__ $$aDataset connected to CrossRef, PubMed,
000137116 650_2 $$2MeSH$$aDiagnosis, Differential
000137116 650_2 $$2MeSH$$aGenome-Wide Association Study
000137116 650_2 $$2MeSH$$aHumans
000137116 650_2 $$2MeSH$$aNeuroimaging
000137116 650_2 $$2MeSH$$aParkinsonian Disorders: diagnosis
000137116 650_2 $$2MeSH$$aParkinsonian Disorders: genetics
000137116 650_2 $$2MeSH$$aParkinsonian Disorders: pathology
000137116 650_2 $$2MeSH$$aRisk Factors
000137116 650_2 $$2MeSH$$aSeverity of Illness Index
000137116 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnosis
000137116 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b1$$eLast author$$udzne
000137116 77318 $$2Crossref$$3journal-article$$a10.1097/wco.0b013e3283632da6$$b : Ovid Technologies (Wolters Kluwer Health), 2013-08-01$$n4$$p401-405$$tCurrent Opinion in Neurology$$v26$$x1350-7540$$y2013
000137116 773__ $$0PERI:(DE-600)2026967-5$$a10.1097/WCO.0b013e3283632da6$$gVol. 26, no. 4, p. 401 - 405$$n4$$p401-405$$q26:4<401 - 405$$tCurrent opinion in neurology$$v26$$x1350-7540$$y2013
000137116 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196800
000137116 909CO $$ooai:pub.dzne.de:137116$$pVDB
000137116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000137116 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000137116 9141_ $$y2013
000137116 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000137116 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000137116 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR OPIN NEUROL : 2017
000137116 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137116 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137116 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137116 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000137116 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000137116 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137116 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137116 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000137116 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137116 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000137116 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000137116 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger 1$$lTranslational Neurodegeneration$$x0
000137116 980__ $$ajournal
000137116 980__ $$aVDB
000137116 980__ $$aI:(DE-2719)1110002
000137116 980__ $$aUNRESTRICTED